- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00086164
Prevention of Vascular Access Graft Failure in Patients With Chronic Renal Failure Requiring Hemodialysis
July 14, 2005 updated by: Anesiva, Inc.
A Phase 1/2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Pilot Trial to Assess the Effect of Treatment of the Recipient Vein of a Polytetrafluoroethylene (PTFE) Vascular Access Graft With Two Concentrations of E2F Decoy as Compared to Placebo on Neointimal Hyperplasia and the Preservation of Graft Function in Patients With Chronic Renal Failure Requiring Hemodialysis
The purpose of this study is to determine the effect of recipient vein pretreatment of edifoligide (E2F Decoy), compared to placebo, on graft/recipient vein stenosis in polytetrafluoroethylene (PTFE) vascular access grafts placed for hemodialysis at 6 months after enrollment.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Angeles, California, United States, 90017
- National Institute of Clinical Research, American Medical Tower
-
-
Florida
-
Hudson, Florida, United States, 34667
- Outcomes Research International, Inc.
-
Miami, Florida, United States, 33136
- University of Miami, School of Medicine
-
Tampa, Florida, United States, 33600
- Tampa General Hospital
-
Tampa, Florida, United States, 33606
- LifeLink Transplant Institute
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University, Renal Division
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- University Transplant
-
Chicago, Illinois, United States, 60617
- Stoney Island Dialysis
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Methodist Hospital, Tower Surgical
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70808
- Vascular Surgery Associates
-
New Orleans, Louisiana, United States, 70112
- Tulane Center For Abdominal Transplant
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Hospital
-
Lansing, Michigan, United States, 48910
- Thoracic & Cardiovascular Healthcare Foundation
-
-
Missouri
-
St. Louis, Missouri, United States, 63110
- St. Louis University, Division of Nephrology
-
-
New York
-
Bronx, New York, United States, 10467
- Montefiore Medical Center
-
New York, New York, United States, 10016
- NYU Medical Center
-
New York, New York, United States, 10025
- St. Luke's Hospital, Department of Surgery
-
Rochester, New York, United States, 14642
- University of Rochester, The Center for Vascular Disease
-
-
South Carolina
-
Greenville, South Carolina, United States, 29605
- Surgical Education
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- University of Utah School of Medicine, Dept of Surgery
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- Nephrology Clinical Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 79 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Be scheduled to undergo placement of a new straight or loop arm PTFE arteriovenous hemodialysis access graft or a Vectragraft® (Thoratec, Inc.)
- Be currently receiving chronic dialysis or be expected to begin hemodialysis within 4 weeks of placement of the index PTFE graft
- Have undergone an assessment of patency (such as venography) of central veins if any of the following conditions have occurred on the ipsilateral arm intended for graft placement: presence of collateral veins, upper extremity edema or increased size (relative to the contralateral arm), history of subclavian catheter, transvenous pacemaker, or history of trauma or surgery that may have involved the neck or chest veins
- Be > 18 and <80 years old
- Have a documented negative serum pregnancy test (for all women of childbearing potential)
- Be using an acceptable method of birth control if of reproductive potential and agree to continue using the birth control for at least 3 months following the graft procedure
- Have agreed to participate voluntarily and have signed and dated an IRB/EC approved, Patient Informed Consent form
Exclusion Criteria:
- Have an intended recipient vein >6 mm or <3 mm in diameter
- Have a history of three or more previous PTFE grafts
- Have uncorrected central vein (including the subclavian vein) stenosis
- Have markedly diminished arterial pulses in the access location (unless adequate flow has been documented by arteriography or Doppler ultrasound)
- Anticipate receipt of a renal transplant within 6 months of enrollment into this study
- Have anticipated use of the index PTFE graft <14 days after enrollment (this does not apply to Vectragraft®)
- Have a known allergy to iodinated contrast
- Have a known hypercoagulable state (e.g., antithrombin III deficiency; antiphospholipid or anticardiolipin antibodies; Factor V Leiden; circulating lupus anticoagulant; current, active, heparin-induced thrombocytopenia; Protein C or S deficiency; or a history of recurrent deep venous thrombosis not related to AV access)
- Have been in another investigational (i.e., nonapproved) drug or device study within the previous 30 days or prior participation in another clinical study with E2F Decoy
- Have been previously enrolled in this study for an earlier access graft
- Have any comorbid, nonrenal condition that makes 6-month survival questionable (e.g., end-stage cancer, advanced heart failure)
- Have a known or suspected history of drug or alcohol abuse within the previous 6 months
- Have a known allergy to any component of the investigational product (drug or device), including latex
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2004
Study Registration Dates
First Submitted
June 25, 2004
First Submitted That Met QC Criteria
June 28, 2004
First Posted (Estimate)
June 29, 2004
Study Record Updates
Last Update Posted (Estimate)
July 19, 2005
Last Update Submitted That Met QC Criteria
July 14, 2005
Last Verified
July 1, 2005
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CGT003-05
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperplasia
-
University of PennsylvaniaFood and Drug Administration (FDA); EUSA Pharma, Inc.; Castleman Disease Collaborative...RecruitingCastleman Disease | Castleman's Disease | Giant Lymph Node Hyperplasia | Angiofollicular Lymph Hyperplasia | Angiofollicular Lymph Node Hyperplasia | Angiofollicular Lymphoid Hyperplasia | GLNH | Hyperplasia, Giant Lymph Node | Lymph Node Hyperplasia, GiantUnited States
-
St. Joseph's Healthcare HamiltonOntario Ministry of Health and Long Term CareCompletedBenign Prostatic HyperplasiaCanada
-
GlaxoSmithKlineCompletedBenign Prostatic Hyperplasia
-
Castleman Disease Collaborative NetworkWithdrawnHyperplasia | Castleman Disease | Castleman's Disease | Giant Lymph Node Hyperplasia | Angiofollicular Lymph Hyperplasia | Angiofollicular Lymph Node Hyperplasia | Angiofollicular Lymphoid Hyperplasia | GLNH | Giant Lymph NodeUnited States
-
Samsung Medical CenterCompletedFocal Nodular HyperplasiaKorea, Republic of
-
Hongguo RongNot yet recruiting
-
SB Istanbul Education and Research HospitalUnknown
-
University of PennsylvaniaCastleman Disease Collaborative NetworkCompletedHyperplasia | Castleman Disease | Castleman's Disease | Giant Lymph Node Hyperplasia | Angiofollicular Lymph Hyperplasia | Angiofollicular Lymphoid Hyperplasia | GLNHUnited States
-
Societatea Romana de Ultrasonografie in Medicina...Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian... and other collaboratorsUnknownLiver Metastases | Focal Nodular Hyperplasia of Liver | Toxic Liver Disease With Focal Nodular HyperplasiaRomania
-
GCS Ramsay Santé pour l'Enseignement et la RechercheNot yet recruiting
Clinical Trials on edifoligide (E2F Decoy)
-
Anesiva, Inc.CompletedIschemia | Arterial Occlusive Diseases | Peripheral Vascular Diseases | Hyperplasia | Graft Occlusion, VascularUnited States, Canada
-
Anesiva, Inc.CompletedCoronary Artery DiseaseUnited States
-
Anesiva, Inc.Completed
-
University of PittsburghCompleted
-
ReNetX Bio, Inc.CompletedChronic Spinal Cord InjuryUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedSotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or AnemiaAnemia | Myelofibrosis | Myelodysplastic/Myeloproliferative NeoplasmUnited States
-
CG Oncology, Inc.CompletedSafety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure (BOND2)Bladder CancerUnited States
-
Geisinger ClinicCompleted
-
TILT Biotherapeutics Ltd.Recruiting
-
TILT Biotherapeutics Ltd.RecruitingMelanoma | Head and Neck Squamous Cell CarcinomaUnited States, Finland